When presented with shocking news concerning the health of his two youngest children, John Crowley responded by embarking on a mission to help uncover a novel therapeutic option for treating Pompe disease, a lysosomal storage disease (LSD) that, like other LSDs, interferes with the body’s ability to break down molecules inside the lysosomes, compartments inside the cell.
This determination has carried over to his leadership role of three companies, and it is what is steering Amicus Therapeutics’ development programs, which are centered around the discovery, development, and commercialization of a new class of small-molecule, orally administered drugs to treat a range of human genetic diseases. These innovative therapies apply to conditions in which crucial proteins are defective…
Finding the Inspiration
Life Meets Work
Pumping up the pipeline